Sydney M Crago

Espansione Group is known for photobiomodulation (PBM) technology – the Light Modulation Low-level Light Therapy (LLLT) along with the Intense Pulsed Light (IPL) technology.

Within 4 months of AEYE-DS's deployment, diabetic retinopathy screening adherence increased from 29 percent to 49 percent.

Kaczmarek has a notable background of executive leadership and operational expertise in the gene therapy manufacturing industry.

This interview comes at the Children's Hospital Los Angeles team celebrates its 100th retinal gene therapy procedure.

The aim of this program is to help advance junior clinical research scientists in their professional endeavors to cure retinal degenerative disease.

This study was published online in the journal Aging Cell and reveals how DNA damage compromises the retina’s function and accelerates vision loss.

Roche, Ainnova, and Salud 360 signed this alliance to improve access to vision screening in patients with uncontrolled diabetes.

ACELYRIN will not make any additional internal investment in developing izokibep.

EXG102 and EXG202 are investigational gene therapy candidates for wet age-related macular degeneration that are in development.

The report is titled, Diabetic Macular Edema Market Insights, Epidemiology, and Market Forecast-2034.

ONS-5010 did not meet the pre-specified non-inferiority endpoint at week 8.

Kim served the Samsung Bioepis as Development Division Leader since December 2021.

This virtual key opinion leader (KOL) event will take place on Wednesday, December 11, 2024, at 4:00 PM ET.

The Foundation has assembled a multidisciplinary team of leading scientists, researchers, and physicians from multiple institutions, all focused on accelerating convergent technologies.

This service will provide researchers with tailored animal models that closely mimic human ocular conditions.

The trial is expected to close randomization in early December 2024.

The presentation and the moderated Q&A is scheduled for Tuesday, December 3, 2024 in Presentation Room 3 at 1:30 pm ET.

Sozinibercept will be featured as part of an oral presentation at the annual FLORetina Congress being held on December 5-8, 2024 in Florence, Italy.

The organization will provide resources for spreading awareness and educating patients and care givers.

With news of several biosimilar candidates moving along the path of approval, Modern Retina is taking a moment to recap the updates on the state of these biosimilars.

Arshad Khanani, MD, MA, FASRS, presented positive data from the phase 2 fellow eye sub-study evaluating the subretinal delivery of ABBV-RGX-314.

Patients treated with investigational oral therapy gildeuretinol (ALK-001) showed a statistically significant reduction in the GA lesion growth rate.

Connell’s appointment was effective immediately after the Annual General Meeting of the Company on November 15, 2024.

Dosing in the first phase of the phase 1/2 OCU410ST GARDian trial for Stargardt disease is complete.

ABI-110 has the potential to offer a durable and effective solution by addressing the root causes of wet AMD at the genetic level.

Study participants include people with no diabetes as well as those with various stages of the condition, creating a set of information distinct from previous research.

Gupta is a nationally recognized retinal surgeon and an entrepreneur whose knowledge and experience on the phases of drug development and medical devices.

The new PDUFA goal date for NT-501 as treatment for macular telangiectasia type 2 (MacTel) is March 18, 2025.

Harrow has announced an initiative to expand access and affordability for its ophthalmic pharmaceutical products.

LUNA is an ongoing double-masked, randomized Phase 2 trial. OPTIC is an ongoing, open-label, dose-ranging first-in-human trial.